TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02758418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAO
Description: TAO is a self-applied online treatment program and consists on the computerized version of the traditional CBT protocol for Adjustment Disorders.~The treatment protocol comprises different therapeutic components (see section Intervention) which are presented to the patients through 7 modules (one of them introductory). The Internet platform allows audiovisual resources (videos, illustrations, music and exercises that provide quick feedback) to be included, that makes the program more interactive.
Study: NCT00000575

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two 100 Og puffs budesonide placebo bid + two 90 Og puffs albuterol prn OR four 2 mg puffs nedocromil placebo bid + two 90 Og puffs albuterol prn.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nedocromil
Description: Four 2 mg puffs bid + two 90 Og puffs albuterol prn

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Two 100 Og puffs bid + two 90 Og puffs albuterol prn.
Study: NCT05198141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole tablets
Description: GI: Patients who were undergoing laparoscopic salpingectomy GII: patients who medically treated with 5 mg d-1 of letrozole using two tablets (2.5 mg of Femara) every day for 10 d GIII patients who medically treated with 10 mg d-1 of letrozole using four tablets (2.5 mg of Femara) every day for 10 d (group III)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole tablets
Description: GI: Patients who were undergoing laparoscopic salpingectomy GII: patients who medically treated with 5 mg d-1 of letrozole using two tablets (2.5 mg of Femara) every day for 10 d GIII patients who medically treated with 10 mg d-1 of letrozole using four tablets (2.5 mg of Femara) every day for 10 d (group III)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic salpingectomy
Description: laparoscopic salpingectomy
Study: NCT03002896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pep-Pal
Description: Pep-Pal is designed to complement the utilization of other resources, provide support when no other resources can be obtained, or provide support in the interim until greater resources can be obtained. In this way, Pep-Pal is a resource for our most hard to reach caregivers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Study: NCT04409613

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education and counseling
Description: All patients or their caregivers will receive twenty minutes educational sessions for the first three visits according to patient ability to understand. At subsequent visits along the study duration, we will briefly review our educational material to refresh the patient's information. This will include: The objectives of treatment, disease progression process, risk factors, common symptoms of bleeding/thrombotic events and how to deal with this. Lifestyle modifications, including smoking cessation, blood pressure and diabetes control. Drug information: drug action, dose, indication, possible side effects, how to deal with the side effects, actions to take when missing the dose, storage conditions and when and how to administer. Possible interactions including drug-drug and drug-food interactions. Target INR and INR monitoring
Study: NCT02146183

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate steviol glycosides
Description: To investigate if intake of stevioside in addition to a carbohydrate-containing composition after work related depletion of muscle glycogen will increase the rate of glycogen re-synthesis as compared with intake of the carbohydrate-containing composition alone.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Corn Starch
Description: 500 mg/day
Study: NCT00833326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-334543, EGFR/ErbB2 inhibitor; oral
Description: multiple dose, escalating

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, mitotic inhibitor; intravenous
Description: multiple dose, single schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic growth factors; subcutaneous
Description: standard of care
Study: NCT02294266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mephedrone and alcohol
Description: Single oral dose mephedrone~Single oral dose alcohol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mephedrone
Description: Single oral dose mephedrone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: Single oral dose alcohol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose placebo
Study: NCT03807024

Intervention type: DIAGNOSTIC_TEST
Intervention: Bladder diary
Description: 3-day bladder diary: The classification of OAB-wet or OAB-dry is based on the record of the three-day bladder diary of each patient. The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The presence of at least one episode of urgency associated incontinence was defined to be OAB-wet, otherwise, OAB-dry

Intervention type: DIAGNOSTIC_TEST
Intervention: Bladder diary
Description: 3-day bladder diary: The classification of OAB-wet or OAB-dry is based on the record of the three-day bladder diary of each patient. The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The presence of at least one episode of urgency associated incontinence was defined to be OAB-wet, otherwise, OAB-dry
Study: NCT03384199

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose escalation to prostate focal lesion
Description: For each patient the radio-opaque marker (used for treatment verification) will be inserted by ultrasound guidance \& local anaesthetic with an 17ga x 30cm brachytherapy needle that has 1.2mm x 3mm one gold marker. The ultrasound probe (as used for transrectal biopsy) will be introduced rectally with the patient in the left lateral position. After measuring the volume of the prostate and determining the desired position (preferably in the corpus of prostate), three gold markers will be inserted as follows: one into right side, one into left side of the base and the third in the apex of the prostate
Study: NCT02474186

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Patients with metastatic breast cancer and other metastatic solid tumors receiving single-agent chemotherapy will receive 3.5 Gy/fraction to a total dose of 35 Gy/10 fractions over 2 weeks with concurrent systemic therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: chemotherapy agent daily for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: chemotherapy agent weekly for two weeks
Study: NCT00437463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: 2.5mg and increase to 5mg if patient do not develop symptomatic hypotension
Study: NCT01478659

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control study food with no added fiber
Description: Adults consuming their usual diet modified by incorporating yogurt and snack bars without added fiber.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Study food with added fiber
Description: Adults consuming their usual diet modified by incorporating yogurt and snack bars containing 16 g of chicory root fiber (Frutalose®).
Study: NCT00293592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 1 mg per kg as a single dose before initiation of cardiopulmonary bypass

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: 1 mg per kg as a single dose before initiation of cardiopulmonary bypass
Study: NCT02770703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DynaMesh visible mesh
Description: Implantation of a MRI visible mesh

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DynaMesh visible mesh
Description: Implantation of a MRI visible mesh

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DynaMesh visible mesh
Description: Implantation of a MRI visible mesh
Study: NCT02218463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol cream 0.01%
Description: Apply a pea-sized amount to the labial adhesion with lateral traction twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetaphil
Description: Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
Study: NCT04422067

Intervention type: OTHER
Intervention: Fetal cephalometry
Description: Fetal cephalometry

Intervention type: OTHER
Intervention: Fetal cephalometry
Description: Fetal cephalometry
Study: NCT01642381

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Full Motivational Interviewing (FMI)
Description: Relational and technical technical (directive) strategies in counselling sessions to significantly increase commitment strength to reduce drinking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Spirit Only Motivational Interviewing (SOMI)
Description: Empathic and non-directive counselling based on Rogerian psychotherapy model.
Study: NCT04163874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fiasp
Description: Fiasp Insulin delivered in a basal-bolus manner.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fiasp
Description: Fiasp Insulin delivered in a basal-bolus manner.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fiasp
Description: Fiasp Insulin delivered in a basal-bolus manner.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramlintide Acetate
Description: Pramlintide delivered in a basal-bolus manner with a fixed ratio with insulin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo delivered in a basal-bolus manner with a fixed ratio with insulin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo delivered in a basal-bolus manner with a fixed ratio with insulin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas
Description: Tandem insulin pump, dexcom G5 sensor, Nexus 5 cellphone running the iMAP algorithm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Artificial Pancreas
Description: Tandem insulin pump, dexcom G5 sensor, Nexus 5 cellphone running the iMAP algorithm.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Artificial Pancreas
Description: Tandem insulin pump, dexcom G5 sensor, Nexus 5 cellphone running the iMAP algorithm.
Study: NCT01389778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: Metformin ER 1500 mg for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT00259103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serelaxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serelaxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serelaxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03832556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT scan
Description: CT scan with biphasic injection of contrast product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI examination
Description: MRI with injection of contrast
Study: NCT06243302

Intervention type: PROCEDURE
Intervention: OTSC Closure After VAAFT
Description: Under general anesthesia,the fistulas will be drained at least for 8 weeks. Then a video camera will be inserted through the external opening to fulgurate the fistula tract under direct vision. Finally the internal fistula opening will be closed water tight by a circular clip. The patients will be followed up for complications as well as short and long term recurrences
Study: NCT02634255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium elective surgery
Description: Rocuronium onset time in patients undergoing inguinal herniorrhaphy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium emergency surgery
Description: Rocuronium onset time in patients undergoing appendectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ringer Lactate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ringer Lactate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acceleromyography device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acceleromyography device
Study: NCT02060409

Intervention type: GENETIC
Intervention: spliceosome
Description: spliceosome mutations
Study: NCT01258049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether Sublingual Spray
Description: Artemether sublingual spray administered at 3 mg/kg (milligrams per kilogram) at specified timepoints

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quinine
Description: Quinine administered intravenously, 20 mg/kg loading dose followed by 10 mg/kg every eight hours
Study: NCT04410393

Intervention type: PROCEDURE
Intervention: vaginal cuff prolapse surgery
Description: Different surgical methods for the treatment of vaginal cuff prolapse in patients who have previously undergone hysterectomy for benign causes

Intervention type: PROCEDURE
Intervention: vaginal cuff prolapse surgery
Description: Different surgical methods for the treatment of vaginal cuff prolapse in patients who have previously undergone hysterectomy for benign causes
Study: NCT03252158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Availability of healthier vs. less healthy foods
Description: Altering the number of slots containing (a) healthier and (b) less healthy foods or beverages in hospital vending machines.~Changes follow a 2-step process whereby decreases are implemented in a separate study period prior to increases in the contrasting group. Following a 4-week baseline period, all vending machines will be standardised to have 75% healthier drinks and/or 25% healthier snacks (study period 1). Vending machines will be randomly allocated to the order in which they: (1) decrease less healthy foods and increase healthier foods or (2) decrease healthier foods and increase less healthy foods (study periods 2\&3 and 5\&6). After each decrease-increase pair, machines will return to the standardised 75% healthier drinks / 25% healthier snacks (study periods 4 and 7).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Availability of healthier vs. less healthy foods
Description: Altering the number of slots containing (a) healthier and (b) less healthy foods or beverages in hospital vending machines.~Changes follow a 2-step process whereby decreases are implemented in a separate study period prior to increases in the contrasting group. Following a 4-week baseline period, all vending machines will be standardised to have 75% healthier drinks and/or 25% healthier snacks (study period 1). Vending machines will be randomly allocated to the order in which they: (1) decrease less healthy foods and increase healthier foods or (2) decrease healthier foods and increase less healthy foods (study periods 2\&3 and 5\&6). After each decrease-increase pair, machines will return to the standardised 75% healthier drinks / 25% healthier snacks (study periods 4 and 7).
Study: NCT04451096

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics with prebiotic
Description: Patients were instructed to consume one sachet twice daily mixed with a glass of water, before or after meals, for a duration of 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients were instructed to consume one sachet twice daily mixed with a glass of water, before or after meals, for a duration of 8 weeks
Study: NCT01339065

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: determining the effect of low dose sub anesthetic doze of ketamine and placaebo on post operative patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: determining the effect of low dose sub anesthetic doze of ketamine and placaebo on post operative patients
Study: NCT02585440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMX157
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMX157
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMX157
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMX157
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMX157
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral tablet
Study: NCT00284856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: montelukast 10 mg tablet once daily, 6 month treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: fluticasone propionate 250 mcg Placebo (Pbo) twice daily, 6 month treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: fluticasone propionate 250 mcg Placebo (Pbo) twice daily, 6 month treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: fluticasone
Description: fluticasone propionate 250 mcg twice daily, 6 month treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Placebo
Description: montelukast 10 mg Pbo tablet once daily, 6 month treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: montelukast 10 mg Pbo tablet once daily, 6 month treatment period
Study: NCT05359484

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Uroflowmetry
Description: according to urodynamic, patients with weak urine stream were evaluated into 2 groups, either detrusor underactivity or bladder outflow obstruction From uroflowmetry, 5 variables including maximal flow rate (Qmax), average flow rate (Qave), voiding volume (VV), post-void residual urine (PVR), and value of Qmax minus Qaverage (DeltaQ) were obtained.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Uroflowmetry
Description: according to urodynamic, patients with weak urine stream were evaluated into 2 groups, either detrusor underactivity or bladder outflow obstruction From uroflowmetry, 5 variables including maximal flow rate (Qmax), average flow rate (Qave), voiding volume (VV), post-void residual urine (PVR), and value of Qmax minus Qaverage (DeltaQ) were obtained.
Study: NCT05017844

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KSR-001-04
Description: One drop to both eyes four times a day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSR-001-02
Description: One drop to both eyes four times a day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSR-001-03
Description: One drop to both eyes four times a day for 12 weeks
Study: NCT00764634

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (USP sterile saline for injection)
Description: 0.5 mL dose of placebo given by intramuscular injection at Days 0, 28, and 182

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rBV A/B-40 vaccine
Description: 0.5 mL dose of rBV A/B-40 vaccine given by intramuscular injection at Days 0, 28 and 182

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (USP sterile saline for injection)
Description: 0.5 mL dose of placebo given by intramuscular injection at Days 0, 56 and 182

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rBV A/B-40 vaccine
Description: 0.5 mL dose of rBV A/B-40 vaccine given by intramuscular injection at Days 0, 56 and 182
Study: NCT03779646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol Fumarate
Description: Bisoprolol was initiated at a dose of 1.25 mg every 24hr. At subsequent biweekly visits, the bisoprolol dose was increased 1.25mg progressively until a daily dose of 0.2mg/kg or the maximum tolerated dose (The rest heart rate \<75bpm and systolic blood pressure \<90mmHg) is achieved. If the participant feel dizziness or the rest heart rate below 60 bpm or systolic blood pressure below 85mmHg or there is any new onset contraindication to bisoprolol, the doctor will decide to return back to the previous dose or stop bisoprolol. Each time the dose is increased, the medication is administered in an outpatient clinic setting, with assessment of the participant's heart rate, blood pressure, symptoms and ECG. Once reach the target dose, the patients will be followed up every 8 weeks in an face-to-face or video visit. After 12 months , the participants will repeat cardiac MR besides heart rate, blood pressure, symptoms, ECG and brain natriuretic peptide(BNP), echocardiography records.
Study: NCT03886909

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The exercise intervention is at least 2 weeks lasting (till the day transplant is taking place) 5-times weekly resistance training intervention combined with aerobic exercise (mostly walking).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prehabilitation Education
Description: Participant will receive a prehabilitation and stem cell education class which will be held at the Penn State Cancer Institute.
Study: NCT04490408

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: long surgical bypass
Description: long surgical bypass and hybrid approaches in patients with multilevel critical lower limb ischemia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid approach
Description: Hybrid approach including bypass and endovascular revascularization